Additional file 1: of Supporting parents following pregnancy loss: a cross-sectional study of telephone peer supporters

Parent Supporter Survey Questionnaire. (PDF 248 kb

Additional file 2: of The effect of mobile application interventions on influencing healthy maternal behaviour and improving perinatal health outcomes: a systematic review protocol

Search terms and search strategy. This search strategy tailored for PubMed will be adapted for each database. (DOCX 17 kb

Additional file 1: Figure S1. of Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade

The effect of gefitinib-FTY720 combination on proliferation of HCC1806 cells with stable IGFBP-3 knockdown. (A) Decreased IGFBP-3 production by two HCC1806 clones stably expressing shIGFBP-3 (shBP3) compared to two control clones expressing vector alone. (B) Cell proliferation data for combined shBP3 clones (red) compared to combined control clones (blue). Although shBP3 cells proliferate identically to control cells in the absence of treatment (solid symbols), treatment with the gefitinib-FTY720 combination (open symbols) is much more inhibitory to control cells than to cells with decreased IGFBP-3 expression. (C, D) Individual proliferation data for two HCC1806 control clones treated with gefitinib (2 μM), FTY720 (0.5 μM), or the combination. (E, F) Similar data for two HCC1806 shBP3 clones. Data are corrected for confluence at time zero, and are mean values ± SD at each time point for triplicate wells for each treatment. (PDF 420 kb

Additional file 4: Figure S4. of Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade

Correlations among immunohistochemical scores for cleaved caspase-3, Ki67, pEGFR and SphK1, in HCC1806 and MDA-MB-468 xenograft tumors. Data from the experiments are shown in Fig. 6. Correlations were assessed using Pearson’s correlation coefficient with two-tailed P values. (A, C, E) HCC1806 tumors. (A) cleaved caspase-3 vs. Ki67: n = 38, r = -0.602, P < 0.001. (C) Ki67 vs. pEGFR: n = 38, r = 0.576, P < 0.001. E: Ki67 vs. SphK1: n = 24, r = 0.462, P = 0.023. B, D, F: MDA-MB-468 tumors. (B) cleaved caspase-3 vs. Ki67: n = 25, r = -0.705, P < 0.001. D: Ki67 vs. pEGFR: n = 16, r = 0.726, P = 0.001. F: Ki67 vs. SphK1: n = 16, r = 0.614, P = 0.011. (PDF 308 kb

Additional file 5: Figure S5. of Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade

Immunohistochemical analysis of nuclear IGFBP-3 in HCC1806 tumors from control, gefitinib-treated (GEF), FTY720-treated (FTY), and combination-treated mice. (A) Tumors were stained for nuclear IGFBP-3, scored as described under Methods. Representative images from each treatment group (bar = 200 μm). (B) Summary data are mean values ± SEM (n = 6 per group), analyzed by one-way ANOVA followed by post hoc Tukey’s test. * P = 0.005, ** P < 0.001 compared to control; § P < 0.025 compared to combination. (PDF 691 kb

Additional file 1: Table S1. of Gestational age specific stillbirth risk among Indigenous and non-Indigenous women in Queensland, Australia: a population based study

Maternal and pregnancy characteristics by livebirth or stillbirth and Indigenous status. Table S2. Gestational age-specific risk of stillbirth associated with diabetes, hypertension, antepartum haemorrhage and SGA, combined Indigenous and non-Indigenous women, Queensland, mid 2005–2011. Table S3. Effect of Indigenous status on gestational age specific stillbirth risk (Indigenous relative to non-Indigenous). (DOCX 17 kb

Characteristics of post-menopausal women commencing therapy with tamoxifen, anastrozole or letrozole between December 2005 and December 2010.

<p>^a Deep vein thrombosis or pulmonary embolism.</p><p>^b United Kingdom and New Zealand.</p

Diagnosis, pharmacy and procedure codes used to identify history of specified conditions.

<p>Diagnosis, pharmacy and procedure codes used to identify history of specified conditions.</p

Results from multivariate Poisson regression models: impact of clinical and demographic characteristics on commencing different endocrine therapies between January 2004 and December 2010 for post-menopausal women with invasive breast cancer.

<p>Results from multivariate Poisson regression models: impact of clinical and demographic characteristics on commencing different endocrine therapies between January 2004 and December 2010 for post-menopausal women with invasive breast cancer.</p

Australian clinical guidelines for endocrine therapy use in women with hormone-dependent early breast cancer [12], [13].

<p>Australian clinical guidelines for endocrine therapy use in women with hormone-dependent early breast cancer <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0084835#pone.0084835-National1" target="_blank">[12]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0084835#pone.0084835-National2" target="_blank">[13]</a>.</p